The Influence of Coagulopathy on Radiographic and Clinical Outcomes in Patients Undergoing Middle Meningeal Artery Embolization as Standalone Treatment for Nonacute Subdural Hematomas
Walid K. Salah,Matthew C. Findlay,Cordell M. Baker,Jonathan P. Scoville,Michael T. Bounajem,Christopher S. Ogilvy,Justin M. Moore,Howard A. Riina,Elad I. Levy,Adnan H. Siddiqui,Alejandro M. Spiotta,C. Michael Cawley,Alexander A. Khalessi,Omar Tanweer,Ricardo Hanel,Bradley A. Gross,Okkes Kuybu,Brian M. Howard,Alex N. Hoang,Ammad A. Baig,MirHojjat Khorasanizadeh,Aldo A. Mendez Ruiz,Gustavo Cortez,Jason M. Davies,Michael J. Lang,Ajith J. Thomas,Daniel A. Tonetti,Jane Khalife,Georgios S. Sioutas,Kate Carroll,Zachary A. Abecassis,Brian T. Jankowitz,Juan Ruiz Rodriguez,Michael R. Levitt,Peter T. Kan,Jan-Karl Burkhardt,Visish Srinivasan,Mohamed M. Salem,Ramesh Grandhi,Jonathan P Scoville,Michael Bounajem,Christopher Ogilvy,Justin Moore,Howard Riina,Elad I Levy,Alejandro Spiotta,Alexander Khalessi,Bradley Gross,Aldo A Mendez Ruiz,Mike Lang,Daniel Tonetti,Brian Jankowitz,Juan Francisco Ruiz Rodriguez,MIchael Levitt,Peter Kan,Jan Karl Burkhardt
DOI: https://doi.org/10.1089/neu.2023.0413
IF: 4.869
2024-03-13
Journal of Neurotrauma
Abstract:Middle meningeal artery embolization (MMAE) is emerging as a safe and effective standalone intervention for non-acute subdural hematomas (NASHs); however, the risk of hematoma recurrence after MMAE in coagulopathic patients is unclear. To characterize the impact of coagulopathy on treatment outcomes, we analyzed a multi-institutional database of patients who underwent standalone MMAE as treatment for NASH. We classified 537 patients who underwent MMAE as a standalone intervention between 2019 and 2023 by coagulopathy status. Coagulopathy was defined as use of anticoagulation/antiplatelet agents or pre-operative thrombocytopenia (platelets <100,000/μL). Demographics, pre-procedural characteristics, in-hospital course, and patient outcomes were collected. Thrombocytopenia, aspirin use, antiplatelet agent use, and anticoagulant use were assessed using univariate and multivariate analyses to identify any characteristics associated with the need for rescue surgical intervention, mortality, adverse events, and modified Rankin Scale score at 90-day follow-up. Propensity score-matched cohorts by coagulopathy status with matching covariates adjusting for risk factors implicated in surgical recurrence were evaluated by univariate and multivariate analyses. Minimal differences in pre-operative characteristics between patients with and those without coagulopathy were observed. On unmatched and matched analyses, patients with coagulopathy had higher rates of requiring subsequent surgery than those without (unmatched: 9.9% vs. 4.3%; matched: 12.6% vs. 4.6%; both <i>p</i> < 0.05). On matched multivariable analysis, patients with coagulopathy had an increased odds ratio (OR) of requiring surgical rescue (OR 3.95; 95% confidence interval [CI] 1.68-9.30; <i>p</i> < 0.01). Antiplatelet agent use (ticagrelor, prasugrel, or clopidogrel) was also predictive of surgical rescue (OR 4.38; 95% CI 1.51-12.72; <i>p</i> = 0.01), and patients with thrombocytopenia had significantly increased odds of in-hospital mortality (OR 5.16; 95% CI 2.38-11.20; <i>p</i> < 0.01). There were no differences in follow-up radiographic and other clinical outcomes in patients with and those without coagulopathy. Patients with coagulopathy undergoing standalone MMAE for treatment of NASH may have greater risk of requiring surgical rescue (particularly in patients using antiplatelet agents), and in-hospital mortality (in thrombocytopenic patients).
neurosciences,clinical neurology,critical care medicine